Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 257 Breast Neoplasms 173 Neoplasms 170 Colorectal Neoplasms 156 Neoplasm Metastasis 127 Melanoma 120 Prostatic Neoplasms 118 Recurrence 117 Leukemia, Myeloid, Acute 117 Pancreatic Neoplasms 115 Ovarian Neoplasms 112 Multiple Myeloma 104 Lung Neoplasms 96 Stomach Neoplasms 91 Squamous Cell Carcinoma of Head and Neck 86 Triple Negative Breast Neoplasms 85 Glioblastoma 82 Lymphoma 77 Lymphoma, Non-Hodgkin 75 Lymphoma, Large B-Cell, Diffuse 65 Carcinoma, Renal Cell 64 Precursor Cell Lymphoblastic Leukemia-Lymphoma 63 Advanced Solid Tumor 59 Endometrial Neoplasms 58 Carcinoma, Hepatocellular 57 Small Cell Lung Carcinoma 55 Uterine Cervical Neoplasms 53 Sarcoma 53 Myelodysplastic Syndromes 51 Leukemia 50

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × 1 year × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡